FDA Novel Drug Approvals for February
Four novel drugs were approved during the month of February. The listbof all approved drugs are available on the FDA website.
| Name | Yuviwel (navepegritide) |
| Manufacturer | Acendis Pharmaceuticals |
| Disease treated | To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses |
| How it works/why it’s cool | Achondroplasia is a rare genetic condition causing skeletal dysplasia and, for many affected individuals, an increased risk of muscular, neurological, and cardiorespiratory complications. YUVIWEL is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia and to normalize bone and cartilage growth. C-type natriuretic peptide: C-type natriuretic peptide (CNP) is a crucial paracrine regulator playing a key role in vascular remodeling, inhibiting fibrosis, and mediating long bone growth. |
| Name | Loargys (pegzilarginase-nbln) |
| Manufacturer | Immedica Pharma |
| Disease treated | To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction |
| How it works/why it’s cool | ARG1-D is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme. This results in persistent elevation of plasma arginine leading to symptoms such as spasticity, seizures, developmental delay, and intellectual disability. Pegzilarginase provides an exogenous source of human arginase 1 enzyme, which reduces elevated blood arginine levels by converting plasma arginine into urea and ornithine. |
| Name | Bysanti (milsaperidone) |
| Manufacturer | Vanda Pharmaceuticals |
| Disease treated | To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder |
| How it works/why it’s cool | BYSANTI™ (milsaperidone), interconverts to iloperidone. Iloperidone has high affinity for 5-HT2A, α1-adrenergic, α2C-adrenergic, D2, and D3 receptors; moderate affinity for D4, 5-HT6, and 5-HT7 receptors; and low affinity for 5-HT1A, 5-HT2C, D1, and H1 receptors. Iloperidone has some of the receptor-binding characteristics of current atypical antipsychotics, such as a high 5-HT2A/D2 binding ratio, which predicts a better tolerability profile than that of conventional neuroleptics. Additional receptor-binding characteristics distinguish iloperidone from other atypical antipsychotics, including high affinity for α2C-adrenergic receptors, which may result in antidepressant and anxiolytic activity and improved cognitive function. Additionally, low affinity for histamine receptors may reduce the risk of sedation and weight gain. |
| Name | Adquey (difamilast) |
| Manufacturer | Aerotech Biopharma |
| Disease treated | To treat mild to moderate atopic dermatitis (eczema) |
| How it works/why it’s cool | Adquey works by blocking an enzyme called phosphodiesterase 4 (PDE4), which plays a role in skin inflammation and itching. By blocking PDE4, it can change cell signaling and lower certain inflammation signals in the skin. As a new option within the nonsteroidal class, this approval provides another choice for the millions of people in the U.S. with eczema, offering a safer alternative to steroid medicine that can cause long-term side effects. This makes it suitable for regular or extended use, especially in children. |
Sources:
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children
FDA Grants Accelerated Approval to Loargys for Arginase 1 Deficiency
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-approval-of-bysanti-milsaperidone-for-the-treatment-of-bipolar-i-disorder-and-schizophrenia—a-new-chemical-entity-opening-new-horizons-in-psychiatric-innovation-302693941.html
https://www.webmd.com/drugs/updates/fda-approves-adquey-nonsteroidal-ointment-for-mild-to-moderate-eczema